NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹4,430 Cr | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr |
What is the latest Revenue of NATCO PHARMA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹4,430 Cr |
| Mar2024 | ₹3,999 Cr |
| Mar2023 | ₹2,707 Cr |
| Mar2022 | ₹1,945 Cr |
| Mar2021 | ₹2,052 Cr |
How is Revenue of NATCO PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,430 Cr | 10.77 | |
| Mar2024 | ₹3,999 Cr | 47.72 | |
| Mar2023 | ₹2,707 Cr | 39.20 | |
| Mar2022 | ₹1,945 Cr | -5.23 | |
| Mar2021 | ₹2,052 Cr | - | |
Compare Revenue of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹15,571.8 Cr | -8.2% | -4% | -33.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹415,037.0 Cr | -3% | -3.6% | -4.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹170,795.0 Cr | -3.1% | 0.1% | 11.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹133,332.0 Cr | -3.7% | 4% | 18.8% | Stock Analytics | |
| CIPLA | ₹116,933.0 Cr | -1.3% | -4.6% | -1.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,350.2 Cr | -4.2% | -7% | -11.4% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -8.2% |
-4% |
-33.3% |
| SENSEX | -1.7% |
-1.4% |
7% |
You may also like the below Video Courses